Evidence map›Paper›PMID 27802278›Full record

ArticlePLoS medicine2016

Projected Impact of Mexico's Sugar-Sweetened Beverage Tax Policy on Diabetes and Cardiovascular Disease: A Modeling Study.

Luz Maria Sánchez-Romero, Joanne Penko, Pamela G Coxson, Alicia Fernández, Antoinette Mason, Andrew E Moran, Leticia Ávila-Burgos, Michelle Odden, Simón Barquera, Kirsten Bibbins-Domingo

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 6 pooled it
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 6 syntheses or guidelines pooled it, 200 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Luz Maria Sánchez-RomeroCenter for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
Joanne PenkoDepartment of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Pamela G CoxsonDepartment of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Alicia FernándezDepartment of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Antoinette MasonDepartment of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Andrew E MoranDivision of General Internal Medicine, Columbia University Medical Center, New York, New York, United States of America.
Leticia Ávila-BurgosCenter for Health Systems Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
Michelle OddenDepartment of Epidemiology, Oregon State University, Corvalis, Oregon, United States of America.ORCID http://orcid.org/0000-0002-5974-3648
Simón BarqueraCenter for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
Kirsten Bibbins-DomingoDepartment of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
San Francisco General Hospital · USInstituto Nacional de Salud Pública · MXColumbia University Irving Medical Center · USOregon State University · US

Funding

Mentoring in the Context of Improving Care for Latinos with DiabetesK24DK102057 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERNANDEZ, ALICIA · 2014 to 2018
$919k
Modeling Optimal Strategies to Prevent Cardiovascular Events in Older AdultsK01AG039387 · NIA · OREGON STATE UNIVERSITY · PI ODDEN, MICHELLE CHRISTINA · 2012 to 2016
$688k
Enhancing Mexican Capacity for CVD Policy ResearchR03TW009061 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIBBINS-DOMINGO, KIRSTEN, FERNANDEZ, ALICIA · 2013 to 2015
$156k
FIC NIH HHS R03 TW009061NIA NIH HHS K01 AG039387NIDDK NIH HHS K24 DK102057
6 · The paper itself

Abstract

backgroundRates of diabetes in Mexico are among the highest worldwide. In 2014, Mexico instituted a nationwide tax on sugar-sweetened beverages (SSBs) in order to reduce the high level of SSB consumption, a preventable cause of diabetes and cardiovascular disease (CVD). We used an established computer simulation model of CVD and country-specific data on demographics, epidemiology, SSB consumption, and short-term changes in consumption following the SSB tax in order to project potential long-range health and economic impacts of SSB taxation in Mexico. METHODS AND

findingsWe used the Cardiovascular Disease Policy Model-Mexico, a state transition model of Mexican adults aged 35-94 y, to project the potential future effects of reduced SSB intake on diabetes incidence, CVD events, direct diabetes healthcare costs, and mortality over 10 y. Model inputs included short-term changes in SSB consumption in response to taxation (price elasticity) and data from government and market research surveys and public healthcare institutions. Two main scenarios were modeled: a 10% reduction in SSB consumption (corresponding to the reduction observed after tax implementation) and a 20% reduction in SSB consumption (possible with increases in taxation levels and/or additional measures to curb consumption). Given uncertainty about the degree to which Mexicans will replace calories from SSBs with calories from other sources, we evaluated a range of values for calorie compensation. We projected that a 10% reduction in SSB consumption with 39% calorie compensation among Mexican adults would result in about 189,300 (95% uncertainty interval [UI] 155,400-218,100) fewer incident type 2 diabetes cases, 20,400 fewer incident strokes and myocardial infarctions, and 18,900 fewer deaths occurring from 2013 to 2022. This scenario predicts that the SSB tax could save Mexico 983 million international dollars (95% UI $769 million-$1,173 million). The largest relative and absolute reductions in diabetes and CVD events occurred in the youngest age group modeled (35-44 y). This study's strengths include the use of an established mathematical model of CVD and use of contemporary Mexican vital statistics, data from health surveys, healthcare costs, and SSB price elasticity estimates as well as probabilistic and deterministic sensitivity analyses to account for uncertainty. The limitations of the study include reliance on US-based studies for certain inputs where Mexico-specific data were lacking (specifically the associations between risk factors and CVD outcomes [from the Framingham Heart Study] and SSB calorie compensation assumptions), limited data on healthcare costs other than those related to diabetes, and lack of information on long-term SSB price elasticity that is specific to geographic and economic subgroups.

conclusionsMexico's high diabetes prevalence represents a public health crisis. While the long-term impact of Mexico's SSB tax is not yet known, these projections, based on observed consumption reductions, suggest that Mexico's SSB tax may substantially decrease morbidity and mortality from diabetes and CVD while reducing healthcare costs.

Indexed as

Models, TheoreticalAdultAgedAged, 80 and overBeveragesCardiovascular DiseasesComputer SimulationDiabetes Mellitus, Type 2Dietary SucroseFemaleHealth Care CostsHumansIncidenceMaleMexicoMiddle AgedDietary SucroseSweetening Agents

Identifiers

PMID27802278
PMCPMC5089730
OpenAlexW2546564166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.